Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11891120 | 0.88 | MC4R (0.77) | MC4RMC5RMC3R | |
| SCHEMBL11891191 | 0.85 | MC4R (0.75) | MC4RMC5RMC3R | |
| SCHEMBL13123858 | 0.84 | MC4R (0.79) | MC4RMC5RMC3R | |
| SCHEMBL11891169 | 0.84 | MC4R (0.81) | MC4RMC5RMC3R | |
| SCHEMBL11891198 | 0.82 | MC4R (0.73) | MC4RMC5RMC3R | |
| SCHEMBL14226098 | 0.80 | MC4R (0.66) | MC4R | |
| SCHEMBL11891188 | 0.79 | MC4R (0.68) | MC4RMC5RMC3R | |
| SCHEMBL11891186 | 0.78 | MC4R (0.78) | MC4RMC5RMC3R | |
| SCHEMBL11891187 | 0.78 | MC4R (0.78) | MC4RMC5RMC3R | |
| SCHEMBL13123862 | 0.76 | MC4R (0.73) | MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-12-13 | — | — | US | disclosed |
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8227485-B2 | Benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227485-B2 | Benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | MC4R, MC5R, MC1R | MC4R 1/4885JAK2 126/4885JAK1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.